Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2012 - 2026)

Alnylam Pharmaceuticals' Other Operating Expenses history runs 11 years deep, the most recent figure standing at $211.1 million for Q1 2026.

• Quarterly Other Operating Expenses rose 197.18% year-over-year to $211.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $822.0 million (up 150.26% YoY) and the FY2025 annual result came in at $681.9 million, up 110.86% from the prior year.
• Other Operating Expenses was $211.1 million for Q1 2026 at Alnylam Pharmaceuticals, down from $267.7 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $267.7 million in Q4 2025 and bottomed at $35.6 million in Q1 2022.
• A 5-year average of $99.7 million and a median of $84.3 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2024 — Other Operating Expenses dropped 19.56% — and 2026, when it surged 197.18%.
• Alnylam Pharmaceuticals' Other Operating Expenses stood at $51.3 million in 2022, then soared by 67.48% to $85.9 million in 2023, then gained by 19.75% to $102.8 million in 2024, then jumped by 160.39% to $267.7 million in 2025, then slipped by 21.14% to $211.1 million in 2026.
• Business Quant data shows ALNY's Other Operating Expenses at $211.1 million in Q1 2026, $267.7 million in Q4 2025, and $200.2 million in Q3 2025.